Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). Such investors are ...
1h
Replit's CEO says it's dumb to study computer science thinking you can make a 'boatload' at Google
Amjad Masad said that young people who are not deeply interested in computer science should not study it.
Rendering isn’t always immediate or complete. Learn where no-JavaScript fallbacks still protect critical content, links, and ...
Replimune (REPL) has announced that it has no other option but to reduce its workforce and scale back U.S. manufacturing operations after the FDA on Friday declined to approve its lead asset, RP1, ...
News is breaking today that Replimune Group, Inc.'s (REPL) Biologics License Application ("BLA") requesting approval for its drug candidate RP1 (vusolimogene oderparepvec) in the indication of anti-PD ...
After initially setting out plans to lay off dozens of workers in Massachusetts, Replimune Group is now increasing those ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Hosted on MSN
REPL vs IOVA: FDA decision day could test biotech bulls’ conviction on these melanoma plays
・Analysts estimate about 116% upside for REPL, compared to a 124% upside for IOVA from current levels. ・Amtagvi, already approved for melanoma, helped Iovance generate about $264 million in product ...
Hosted on MSN
REPL stock on track for worst drop in nearly 7 months ahead of FDA decision on skin cancer drug
・The FDA issued a complete response letter regarding the application for RP1 in combination with Nivolumab for the treatment of advanced melanoma in late July. ・Following months of engagement between ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results